The CMDv examines question relating to the marketing authorisation of veterinary medicines in two or more European Union (EU) Member States in accordance with the mutual recognition procedure or the decentralised procedure.
In particular, if there is disagreement between Member States during the assessment on the grounds of a potential serious risk to human or animal health or to the environment, the CMDv considers the matter and strives to reach an agreement within a 60-day time period as set out in legislation.
The CMDv was formerly known as the Coordination Group for Mutual Recognition and Decentralised Procedures - Veterinary before 28 January 2022.
The CMDv is composed of one representative per Member State (plus Norway, Iceland and Liechtenstein), appointed for a renewable period of three years. Observers from the European Commission and EU accession countries may also participate in meetings. Information on the CMDv members is available on the CMDv website.
The European Medicines Agency (EMA) provides the secretariat for the CMDv.
The CMDv holds monthly meetings at the EMA lasting two days. Informal meetings may also be held in the Member State holding the rotating EU presidency.
The CMDv meeting reports are available on the CMDv website.
The CMDv website contains further information on the CMDv and its work, including statistics, guidance documents, question-and-answer documents, work plans and annual reports.